RNAZ
TransCode Therapeutics, Inc. NASDAQ Listed Jul 8, 2021$4.99
After hrs
$5.00
+2.99%
Mkt Cap $4.7M
52w Low $3.82
6.8% of range
52w High $20.99
50d MA $6.82
200d MA $9.12
P/E (TTM)
—
EV/EBITDA
—
P/B
0.3x
Debt/Equity
0.0x
ROE
-335.4%
P/FCF
-0.2x
RSI (14)
45.10
ATR (14)
$0.78
Beta
1.50
50d MA
$6.82
200d MA
$9.12
Avg Volume
101.5K
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
CIK (SEC)
Phone
857-837-3099
6 Liberty Square · Boston, MA 02109 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15, 2026 | AMC | -10.08 | -18.58 | -62.9% | 8.91 | -2.5% | -2.4% | +1.1% | +1.0% | -0.2% | -3.0% | — |
| Nov 14, 2025 | AMC | -9.24 | -5.49 | +40.6% | 9.24 | -2.6% | +1.8% | -4.0% | -0.4% | -4.8% | +0.9% | — |
| Aug 14, 2025 | AMC | -8.68 | -4.94 | +43.1% | 11.05 | +5.9% | -2.4% | -2.7% | -6.7% | +3.4% | -7.0% | — |
| May 14, 2025 | AMC | -3.21 | -16.81 | -423.7% | 9.71 | -15.0% | -21.2% | +6.7% | -17.9% | +4.6% | +13.3% | — |
| Mar 28, 2025 | AMC | -105.93 | -16.61 | +84.3% | 13.72 | -7.4% | +1.0% | +9.3% | -2.3% | -12.6% | -0.9% | — |
| Nov 14, 2024 | AMC | -16.17 | -5.28 | +67.3% | 226.52 | -3.1% | -3.0% | -2.9% | -0.7% | +2.5% | +13.1% | — |
| Aug 14, 2024 | AMC | -19.14 | -24.42 | -27.6% | 147.28 | +1.3% | +9.9% | +6.6% | +1.3% | +1.9% | +1.6% | — |
| May 15, 2024 | AMC | -23.10 | -21.45 | +7.1% | 521.64 | -0.8% | +9.7% | +30.0% | +3.5% | +4.9% | +15.5% | — |
| Mar 29, 2024 | AMC | -10.80 | -99.99 | -825.8% | — | — | — | — | — | — | — | — |
| Nov 14, 2023 | AMC | -1980.20 | -2217.82 | -12.0% | 8200.64 | -1.2% | -9.3% | -9.6% | +0.8% | -12.6% | +0.7% | — |
| Aug 14, 2023 | AMC | -4475.25 | -4343.23 | +3.0% | 42688.80 | +3.0% | -1.8% | -1.2% | +1.9% | +0.6% | +0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.14 | $10.95 | -1.7% | -10.4% | -23.5% | +10.1% | +3.7% | +0.9% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.99 | $17.89 | -10.5% | -27.3% | +4.8% | +0.3% | +4.4% | -6.7% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $222.88 | $213.92 | -4.0% | -13.3% | +19.7% | -8.2% | -0.4% | -1.2% |
| Feb 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $175.28 | $222.04 | +26.7% | +27.2% | -13.3% | +19.7% | -8.2% | -0.4% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $123.76 | $81.76 | -33.9% | -38.0% | -1.5% | -2.6% | -4.6% | -2.0% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $226.52 | $219.52 | -3.1% | -3.0% | -2.9% | -0.7% | +2.5% | +13.1% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $435.40 | $427.00 | -1.9% | -3.5% | -9.6% | +1.6% | -6.2% | -10.0% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $178.08 | $177.52 | -0.3% | -4.1% | -3.1% | +0.2% | +1.4% | -2.5% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $147.28 | $149.24 | +1.3% | +9.9% | +6.6% | +1.3% | +1.9% | +1.6% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1254.40 | $1113.28 | -11.2% | -25.0% | +12.5% | +8.9% | -8.8% | -16.4% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $521.64 | $517.44 | -0.8% | +9.7% | +30.0% | +3.5% | +4.9% | +15.5% |
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $346.92 | $342.72 | -1.2% | -5.8% | -0.7% | +0.1% | -3.4% | -5.4% |
| Apr 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $441.28 | $436.80 | -1.0% | -4.7% | +4.6% | -5.9% | +2.4% | -2.2% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7926.24 | $9447.20 | +19.2% | +40.4% | -13.7% | +12.2% | -21.6% | +10.4% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43080.80 | $43723.68 | +1.5% | -0.9% | -1.8% | -1.2% | +1.9% | +0.6% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $265705.44 | $290597.44 | +9.4% | +6.7% | -0.1% | +0.5% | -3.7% | -8.5% |
| Jun 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
No insider trades available.
8-K · 7.01
! Medium
TransCode Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 18
8-K · 8.01
!! High
TransCode Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 3
8-K
TransCode Therapeutics, Inc. -- 8-K Filing
Jun 1
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
RNAZ's new material agreement with YA II PN, LTD. could signal partnership or financing that affects growth prospects, making this worth monitoring for detailed terms affecting shareholder value.
Apr 7
NT 10-K
!!! Very High
Unknown — Late Annual Report — Distress Signal
RNAZ's delayed annual report filing signals potential financial distress or operational problems, likely triggering exchange delisting concerns and causing investors to reassess the company's viability and governance.
Mar 31
8-K · 8.01
!! High
TransCode Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
TransCode Therapeutics announced a material event requiring SEC disclosure, though specific details weren't provided in the summary excerpt.
Mar 3
8-K · 7.01
! Medium
TransCode Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
TransCode Therapeutics published research on its RIG-I agonist cancer immunotherapy platform in Molecular Imaging and Biology, potentially validating its scientific approach and strengthening intellectual property positioning.
Feb 23
8-K · 7.01
! Medium
TransCode Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
TransCode Therapeutics advanced its lead cancer candidate TTX-MC138 toward Phase 2a testing through an FDA IND amendment submission, potentially expanding clinical development and de-risking the pipeline.
Feb 5
Institutional (13F) — Top 4
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Ubs Group Ag | 8,295 | $71K | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 6,545 | $56K | New | Mar 2026 |
| 3 | Wells Fargo & Company/mn | 55 | $474 | New | Mar 2026 |
| 4 | Royal Bank Of Canada | 8 | — | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 5,783 | $58K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 1,180 | $12K | Feb 2026 |
| 3 | Fidelity Total Market Index Fund | 510 | $5K | Feb 2026 |
Valuation
Market Cap
$4.7M
Enterprise Value
-$14.4M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.01x
P/B
0.33x
P/S
—
P/FCF
-0.18x
EV/EBITDA
—
Shares Out
690K
Financials (TTM)
Revenue
$0
Net Income
-$40.4M
EBITDA
-$39.8M
Free Cash Flow
-$19.5M
Op Cash Flow
-$19.5M
EPS Basic
$-52.59
EPS Diluted
$-48.65
EPS Forward
$-8.96
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$162.4M
Total Liab.
$152.1M
Total Equity
$10.3M
Cash
$17.8M
LT Debt
$0
Book Value/Sh
$14.99
Debt/Equity
0.00x
Current Ratio
6.29
Quick Ratio
6.29
Returns & Growth
ROE
-335.4%
ROA
-21.3%
ROIC
-17.6%
Rev Growth YoY
+0.0%
EPS Growth YoY
-11.6%
Price Returns
2W
-24.3%
1M
-35.8%
3M
-46.5%
6M
-44.7%
12M
-24.3%
Technicals
52W High
$20.99
52W Low
$3.82
50d MA
$6.82
200d MA
$9.12
RSI (14)
45.10
ATR (14)
$0.78
Beta
1.50
Avg Volume
102K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 11:12pm
· Source: financialmodelingprep.com